eFFECTOR Therapeutics BST:LWK1 Stock Report Company Financials + 2 Analysts
eFFECTOR Therapeutics, Inc.
BST:LWK1 Stock Report
LWK1 Stock Overview A biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer.
Rewards Risk Analysis + 2 more risks
See All Risk Checks eFFECTOR Therapeutics, Inc. Competitors Price History & Performance
Summary of all time highs, changes and price drops for eFFECTOR Therapeutics Historical stock prices Current Share Price US$10.36 52 Week High US$21.84 52 Week Low US$9.30 Beta 0.52 11 Month Change 0% 3 Month Change 0.31% 1 Year Change n/a 33 Year Change n/a 5 Year Change n/a Change since IPO -98.18%
Recent News & Updates
eFFECTOR Therapeutics Files Form 15 Jul 31
eFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index Jul 04
eFFECTOR Therapeutics Provides Non-Compliance Update Jun 26 eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term
eFFECTOR Therapeutics, Inc. Receives Written Notice from Nasdaq Regarding Minimum Value of Listed Securities May 18 eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. May 10
See more updates
eFFECTOR Therapeutics Files Form 15 Jul 31
eFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index Jul 04
eFFECTOR Therapeutics Provides Non-Compliance Update Jun 26 eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term
eFFECTOR Therapeutics, Inc. Receives Written Notice from Nasdaq Regarding Minimum Value of Listed Securities May 18 eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. May 10
eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 13, 2024 Apr 28
eFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer Apr 04 eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.000003 million. Jan 30
eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.000003 million. Jan 25
eFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients Dec 08
eFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer Nov 29
Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia (Aml) Oct 25
eFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors Sep 12
eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq Stock Market Regarding Non-Compliance with Nasdaq's Minimum Bid Price Requirement Aug 06 eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.733186 million. Jun 09
eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million. Jun 02
eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million. Jun 01
Shareholder Returns LWK1 DE Biotechs DE Market 7D 0% -2.2% 1.1% 1Y n/a -17.1% 13.5%
See full shareholder returns
Return vs Market: Insufficient data to determine how LWK1 performed against the German Market .
Price Volatility Is LWK1's price volatile compared to industry and market? LWK1 volatility LWK1 Average Weekly Movement n/a Biotechs Industry Average Movement 5.8% Market Average Movement 4.7% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: LWK1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LWK1's volatility change over the past year.
About the Company eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer.
Show more eFFECTOR Therapeutics, Inc. Fundamentals Summary How do eFFECTOR Therapeutics's earnings and revenue compare to its market cap? LWK1 fundamental statistics Market cap €57.93m Earnings (TTM ) -€33.01m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LWK1 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$35.81m Earnings -US$35.81m
Last Reported Earnings
Dec 31, 2023
Earnings per share (EPS) -7.84 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -353.5%
How did LWK1 perform over the long term?
See historical performance and comparison
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
